Markets:

Overview

News

Currencies

International

Treasuries

Catalent, Inc. Common Stock (NY:CTLT)

63.48 UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Catalent, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗

February 26, 2024

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.

Via Benzinga

In-Depth Examination Of 5 Analyst Recommendations For Catalent ↗

February 20, 2024

Via Benzinga

Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest? ↗

February 14, 2024

Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.

Via Benzinga

Topics Stocks

Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs ↗

February 12, 2024

Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...

Via Benzinga

Earnings Outlook For Catalent ↗

February 08, 2024

Via Benzinga

Why Catalent Stock Soared Today ↗

February 05, 2024

Catalent has agreed to be acquired by Novo Nordisk's parent company.

Via The Motley Fool

Analyst Expectations For Catalent's Future ↗

January 25, 2024

Via Benzinga

Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now? ↗

February 11, 2024

Even more revenue is on the way from additional sales of Wegovy.

Via The Motley Fool

Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited ↗

February 10, 2024

Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.

Via The Motley Fool

US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March ↗

February 09, 2024

The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory.

Via Benzinga

Earnings Scheduled For February 9, 2024 ↗

February 09, 2024

Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.

Via Benzinga

What Happened With Caltalent Stock? ↗

December 19, 2023

Catalent, Inc. (NYSE: CTLT) shares traded higher on Tuesday. Following losses at the end of October, the stock has rebounded over the past month.

Via Benzinga

The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry ↗

February 08, 2024

Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.

Via Benzinga

Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns ↗

February 07, 2024

Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.

Via Benzinga

Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks ↗

February 06, 2024

Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry.

Via InvestorPlace

Catalent Analysts Raise Their Forecasts Following Acquisition News ↗

February 06, 2024

On Monday, Catalent, Inc. (NYSE: CTLT) announced it will be acquired by Novo Holdings. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

Via Benzinga

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Novo Nordisk Stock Crushed the Market on Monday ↗

February 05, 2024

The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition.

Via The Motley Fool

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? ↗

February 05, 2024

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...

Via Benzinga

Topics Economy

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record ↗

February 05, 2024

Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs.

Via Investor's Business Daily

What's Going On With Eli Lilly Stock Today? ↗

February 05, 2024

Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound.

Via Benzinga

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 05, 2024

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS...

Via Benzinga

Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk ↗

February 05, 2024

Catalent stock is rising higher on Monday after the company announced a $16.5 billion cash acquisition deal for CTLT shares.

Via InvestorPlace

Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday ↗

February 05, 2024

U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday.

Via Benzinga

Topics Stocks

Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand ↗

February 05, 2024

This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

February 05, 2024

The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning!

Via InvestorPlace

S&P 500 Shatters Records: The Top-Performing Stocks In January 2024 ↗

January 19, 2024

2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD.

Via Benzinga

Topics Artificial Intelligence Stocks

These 9 Stocks Are Running To Start 2024 ↗

January 14, 2024

The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.

Via Investor's Business Daily

Topics Stocks

Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality' ↗

November 30, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vishay Intertechnology, Inc.

Via Benzinga

Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 16, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Catalent, Inc. Common Stock (NY:CTLT)

Headline News about Catalent, Inc. Common Stock

Starting at $3.75/week.

Subscribe Today